Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

May 29, 2025

PresentationFiclatuzumab

FIERCE-HN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab (HGF/c-MET MAb) in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

May 29, 2025

PresentationTivozanib

Efficacy of second line (2L) treatment with Tivozanib (Tivo) as monotherapy or with Nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the Phase 3 TiNivo-2 study

May 29, 2025

PresentationAV-380

A Phase 1b Dose Escalation Study of AV-380 (Anti-GDF15 Monoclonal Antibody) in Combination with Standard-of-Care Therapy in Cancer Patients with Cachexia

February 13, 2025

PresentationTivozanib

Integrated Efficacy and Safety Exposure Response (ER) Analysis of Tivozanib (Tivo) for the Treatment of Renal Cell Carcinoma (RCC)

February 13, 2025

PresentationTivozanib

Patient-Reported Outcomes (PROs) for Tivozanib + Nivolumab (Tivo-Nivo) vs. Tivozanib (Tivo) Monotherapy in Patients With Renal Cell Carcinoma (RCC) Following an Immune Checkpoint Inhibitor (ICI): Results of the Phase 3 TiNivo-2 Study

January 6, 2025

PublicationTivozanib

Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study

Authors: Miguel Zugman, David F. McDermott, Bernard J. Escudier, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael B. Atkins, Brian Rini, Sumanta K. Pal. Click here for link to article.

1 2 3 … 15 Next »